XLO (Xilio Therapeutics) Accumulated Depreciation: $-9.41 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XLO Xilio Therapeutics Inc XLO
32 GF Score
Price $9.00
! 2 Warning Signs
View Full Analysis

What is Xilio Therapeutics Accumulated Depreciation?

Xilio Therapeutics XLO +0.52% 32 Accumulated Depreciation is $-9.41 Mil as of Jun. 2026. GuruFocus rates XLO with a GF Score™ of 32/100. The stock has 2 warning signs investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Xilio Therapeutics's quarterly accumulated depreciation increased from Dec. 2025 ($-8.75 Mil) to Mar. 2026 ($-9.10 Mil) and increased from Mar. 2026 ($-9.10 Mil) to Jun. 2026 ($-9.41 Mil).

Xilio Therapeutics's annual accumulated depreciation increased from Dec. 2023 ($-5.86 Mil) to Dec. 2024 ($-7.43 Mil) and increased from Dec. 2024 ($-7.43 Mil) to Dec. 2025 ($-8.75 Mil).

Xilio Therapeutics Accumulated Depreciation Related Terms

Xilio Therapeutics Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for Xilio Therapeutics's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xilio Therapeutics Accumulated Depreciation Chart

Xilio Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accumulated Depreciation
Get a 7-Day Free Trial -2.71 -4.42 -5.86 -7.43 -8.75

Xilio Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.12 -8.46 -8.75 -9.10 -9.41
XLO
32GF Score
Xilio Therapeutics Inc XLO
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xilio Therapeutics Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of $-9.41 Mil mean?
Xilio Therapeutics (XLO) has a Accumulated Depreciation of $-9.41 Mil as of Jun. 2026. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Xilio Therapeutics and its competitors.
Is Xilio Therapeutics' Accumulated Depreciation too high?
Xilio Therapeutics' current Accumulated Depreciation is $-9.41 Mil. Overall, Xilio Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Xilio Therapeutics' Accumulated Depreciation compare to INKT and IMA?
Xilio Therapeutics' Accumulated Depreciation of $-9.41 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Biotechnology company?
A good Accumulated Depreciation depends on the Biotechnology industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Xilio Therapeutics and its competitors. Xilio Therapeutics's current Accumulated Depreciation is $-9.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xilio Therapeutics stock overvalued right now?
Xilio Therapeutics (XLO) has a current Accumulated Depreciation of $-9.41 Mil. The current Accumulated Depreciation is $-9.41 Mil. Xilio Therapeutics' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For Xilio Therapeutics (XLO), the current Accumulated Depreciation is $-9.41 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Xilio Therapeutics Business Description

Address 828 Winter Street, Suite 300, Waltham, MA, USA, 02451
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.
32GF Score

Get the complete analysis for XLO

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.00
Price